HPTN=HIV Prevention Trials Network.
HPTN 084 Efficacy
In a clinical study (double-blind phase)
APRETUDE delivered superior efficacy with significantly lower incidence of HIV-1 infection vs a daily oral PrEP (TDF/FTC)
§An initial analysis showed 4 incident infections in the APRETUDE arm (hazard ratio [95% CI]: 0.12 [0.05-0.31]). Retrospective testing showed 1 of the 4 to be a prevalent infection, resulting in 3 incident infections.
CI=confidence interval; INSTI=integrase strand transfer inhibitor; NRTI=nucleoside/nucleotide reverse transcriptase inhibitor; PrEP=pre-exposure prophylaxis.
Cumulative incidence of HIV-1 infections in HPTN 084
Cumulative events are the overall number of HIV infections in each arm over time.4
HPTN 084 Resistance Profile
Resistance mutations3
- No resistance-associated mutations (RAMs) were detected in participants receiving APRETUDE3
- Of the infections in the APRETUDE arm, no major INSTI RAMs were detected
- Of the incident infections in the TDF/FTC arm, NRTI RAMs were detected in 1 of the participants3
HPTN 084 Adherence Subset Analysis
Based on an analysis of tenofovir concentrations in dried blood spots from a randomly selected subset of 405 participants in the TDF/FTC arm (secondary endpoint)1
82% of participants appeared to take ≤4 TDF/FTC doses per week1
Figure shows the proportion of participants with drug concentrations measured in dried blood spots reflecting ≤4 doses/week (<700 fmol/punch) or 4-7 doses/week (≥700 fmol/punch) tenofovir use over the previous 1 to 2 months.1
Individuals should strictly adhere to the recommended dosing schedule for prescribed PrEP.
CDC guidelines recommend cisgender women taking daily oral PrEP be 100% adherent, meaning 7 days a week.5
CDC=Centers for Disease Control and Prevention; fmol=femtomole.
View expert discussions
Watch Dr Zandraetta Tims-Cook discuss the efficacy and safety of APRETUDE.
Real HCP compensated by ViiV Healthcare.
CBTWCNT230041
References:
Delany-Moretlwe S, Hughes JP, Bock P, et al; HPTN 084 study group. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi:10.1016/S0140-6736(22)00538-4
Evaluating the safety and efficacy of long-acting injectable cabotegravir compared to daily oral TDF/FTC for pre-exposure prophylaxis in HIV-uninfected women. ClinicalTrials.gov identifier: NCT03164564. Published May 23, 2017. Updated March 28, 2023. Accessed August 2, 2023. https://clinicaltrials.gov/ct2/show/NCT03164564
Eshleman SH, Fogel JM, Piwowar-Manning E, et al. Characterization of HIV infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis. 2022;225(10):1741-1749. doi:10.1093/infdis/jiab57
HIV Prevention Trials Network. HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) for Pre-Exposure Prophylaxis in HIV-Uninfected Women (protocol version 3.0; August 12, 2021). Accessed August 2, 2023. https://www.hptn.org/research/studies/hptn084#views-field-field-public-files
Centers for Disease Control and Prevention. HIV Surveillance Report, 2020. Vol 33. May 2022. Updated May 24, 2022. Accessed August 2, 2023. https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html